๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

RecruitingPhase 2, Phase 3Ages 18 Years - anyAllNational Institute of Geriatrics, Rheumatology anโ€ฆ
NCT06011889 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Diagnosis of SAPHO syndrome according to modified Kahn criteria from 2003. 2. Age over 18. 3. Patient overall disease and pain assessment on VAS both โ‰ฅ 4 cm. 4. Expressing informed consent to participate in the study. Exclusion Criteria: 1. According to the Summary of Product Characteristics (SmPC) for Enbrel. 2. Pregnancy, breastfeeding, inability to use effective contraception during the examination. 3. Change in the dose of NSAIDs treatment in the last 4 weeks. 4. Dose modification of disease-modifying antirheumatic drugs (DMARDs) over the past 12 weeks. 5. Use of biological drugs / synthetic targeted drugs in the last 12 weeks. 6. Use of corticosteroids (orally or local injections), bisphosphonates and/or antibiotics in the last 4 weeks. 7. Any medical condition that the investigator judges to contraindicate etanercept treatment.
๐Ÿ’Š

What it tests

  • Etanercept
  • Placebo
๐Ÿ“

Where

1 site
Centrum Wsparcia Badaล„ Klinicznych
Warsaw, Poland
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy